<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">

A Needle in a Haystack – Finding Rare AML Cell Populations by Flow Cytometry

Jun 10, 2021 11:00:00 AM / by Champions Oncology posted in Hematological Malignancies, Preclinical Flow Cytometry

Hematologic malignancies include a wide array of lymphomas and leukemias that affect different immune cell subsets. Acute myelogenous leukemia (AML) is one of the most commonly occurring leukemias in adults and children. AML is a highly heterogenous disease that can be caused by spontaneous gene mutations or chromosomal translocations, which results in the proliferation of dysfunctional myeloid cells. Cytogenetic and morphologic analyses have been the gold standard methods used in AML diagnosis, but flow cytometry-based protocols are becoming more widely used and validated as complementary diagnostic methods that can be coupled with these analyses to better guide treatment plans. Flow cytometry has also become an essential tool to understand AML progression and develop and evaluate novel therapeutics.

Consider these aspects of flow cytometry-based analysis of AML for exploratory or preclinical research.

Read More →